Elizabeth L. Schwartz

Elizabeth L. Schwartz

Auto-generated profile, based on publicly available information

Elizabeth L. Schwartz

Division of Epidemiology and Community Health, University of Minnesota School of Public Health , Minneapolis, Minnesota

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2021 in Health & Place
Verified
Journal Article
Closed access
ESElli Schwartz
Elli Schwartz
NONathaniel Onnen
Nathaniel Onnen
PCPeter F. Craigmile
Peter F. Craigmile
MRMegan E Roberts
Megan E Roberts

8 October 2025 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
ESElizabeth L Schwartz
Elizabeth L Schwartz
ENElizabeth K Nalintya
Elizabeth K Nalintya
CSCaleb Skipper
Caleb Skipper
PNPatricia Nerima
Patricia Nerima
AFAnn M Fieberg
Ann M Fieberg
RRRadha Rajasingham
Radha Rajasingham
Background: People with advanced human immunodeficiency virus (HIV) disease (CD4 ≤ 200 cells/µL) remain at high risk for opportunistic infections, hospitalization, and death, despite access to antiretroviral therapy (ART). We evaluated serum C-reactive protein (CRP) as a predictor of 30-day hospitalization or death among outpatients with advanced HIV disease. Methods: We prospectively enrolled 1388 outpatient Ugandan adults with CD4 ≤ 200 cells/µL from May 2022 to February 2025, of whom 1378 had serum CRP measured at enrollment. Participants were ART-naïve or experienced, and people with known virologic suppression were excluded. Participants received tuberculosis and cryptococcosis screening and therapy per World Health Organization (WHO) recommendations. We examined CRP as a continuous and dichotomized predictor (≥10 mg/L) of 30-day hospitalization or death. Results: Among 1378 participants, 41.6% had CRP ≥10 mg/L. Participants with CRP ≥10 mg/L were more likely to be hospitalized (relative risk = 4.2, 95% CI: 2.3–7.8) or die (relative risk = 9.8, 95% CI: 2.9–32.8) within 30 days. In a multivariable Cox model adjusted for weight, CD4 count, ART status, and age, each 2-fold increase in CRP was associated with a 36.9% higher hazard of 30-day hospitalization or death (hazard ratio = 1.4, 95% CI: 1.2–1.5). Including CRP in the multivariable model significantly improved prediction of 30-day hospitalization or death (AUC 0.80 with CRP vs 0.72 without, DeLong's P = .009). Conclusions: CRP ≥10 mg/L is associated with increased risk of 30-day hospitalization or death among outpatients with advanced HIV disease receiving the WHO-recommended package of care. Prospective studies should evaluate whether point-of-care CRP testing can enable real-time risk stratification to reduce AIDS-related deaths.

28 February 2026 in Medical Mycology
Verified
Journal Article
Closed access
MOMadison Okuno
Madison Okuno
ESElizabeth L Schwartz
Elizabeth L Schwartz
KBKaitlin Benedict
Kaitlin Benedict
JMJason Massey
Jason Massey
DBDavid R Boulware
David R Boulware
Nathan C BahrNathan C Bahr
Nathan C Bahr
Elevated intracranial pressure contributes to high mortality in cryptococcal meningitis. We evaluated the association between therapeutic lumbar punctures (LPs) and survival among patients hospitalized with cryptococcal meningitis in the United States. Repeat LPs were associated with lower mortality (hazard ratio [HR] 0.38; 95% confidence interval (CI), 0.29–0.49) overall, in people with HIV (HR 0.33; 95% CI, 0.21–0.50), in transplant recipients (HR 0.21; 95% CI, 0.08–0.58), and in persons without HIV or transplant (HR 0.44; 95% CI, 0.30–0.64) compared with receipt of only diagnostic LP. Findings support guideline-recommended repeat LP across diverse populations.

24 July 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
HDHoracio A Duarte
Horacio A Duarte
JCJames G Carlucci
James G Carlucci
ESElizabeth L Schwartz
Elizabeth L Schwartz
NSNadia Sam-Agudu
Nadia Sam-Agudu
EEEva Enns
Eva Enns
JBJeanette K Birnbaum
Jeanette K Birnbaum
Background: Switching to injectable long-acting cabotegravir and rilpivirine (LA-CAB/RPV) may improve viral suppression among pregnant and breastfeeding women (PBFW) who have persistent viremia on first-line antiretroviral therapy (ART), resulting in the prevention of vertical transmission (PVT). Methods: We used a microsimulation model of PBFW living with HIV in Kenya on dolutegravir-based first-line ART to evaluate the PVT potential of LA-CAB/RPV in 2 maternal populations—newly positive (NP) pregnant women who initiate ART during antenatal care, and known positive (KP) women who initiate ART prior to conception—during antenatal care through 18 months postpartum. For each population, we modeled a standard of care (SOC) without access to a second-line regimen, and a strategy with LA-CAB/RPV as a second-line regimen. Both strategies implement routine maternal viral load (VL) monitoring every 6 months and account for an imperfect cascade, including a 50% probability of regimen switching among eligible PBFW in the LA-CAB/RPV strategy. Results: The average time from having unsuppressed VL to switching regimens was over 8 months, and 5.1% of NP and 8.2% of KP women ultimately switched. Compared to SOC, the LA-CAB/RPV strategy reduced vertical transmission by 1.2% for NP and 4.2% for KP women. These reductions increased to 4.0% and 11.5%, respectively, when assuming perfect adherence to more frequent VL monitoring (3-month intervals) and 100% regimen switching when eligible. Conclusions: Supporting high switching rates and decreasing delays in switching will help optimize the PVT impact of second-line LA-CAB/RPV among PBFW who accept this regimen.

3 October 2025 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
ESElizabeth L. Schwartz
Elizabeth L. Schwartz
Nathan C BahrNathan C Bahr
Nathan C Bahr
RRRadha Rajasingham
Radha Rajasingham